Chromosomal instability is associated with higher expression of genes implicated in epithelial-mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance

Neoplasia

Volumn 10, Issue 11, 2008, Pages 1222-1230

  Roschke, Anna V ^a   Glebov, Oleg K ^a   Lababidi, Samir ^a   Gehlhaus, Kristen S ^a   Weinstein, John N ^a   Kirsch, Ilan R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOLOGY; CANCER CELL; CANCER INVASION; CELL ADHESION; CELL COMMUNICATION; CELL CYCLE; CELL FUNCTION; CELL MIGRATION; CELL MOTILITY; CELL POPULATION; CHROMATIN; CHROMOSOMAL INSTABILITY; CHROMOSOME LOSS; DNA REPAIR; EPITHELIUM; GENE; GENE EXPRESSION; KARYOTYPE; MESENCHYME CELL; METASTASIS; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL;

EID: 55849123268     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08682     Document Type: Article

References (41)

1. Mitelman F, Johansson B, Mandahl N, and Mertens F (1997). Clinical significance of cytogenetic findings in solid tumors. Cancer Genet Cytogenet 95, 1-8.
2. Ried T, Heselmeyer-Haddad K, Blegen H, Schrock E, and Auer G (1999). Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer 25, 195-204.
3. Pandis N, Idvall I, Bardi G, Jin Y, Gorunova L, Mertens F, Olsson H, Ingvar C, Beroukas K, Mitelman F, et al. (1996). Correlation between karyotypic pattern and clincopathologic features in 125 breast cancer cases. Int J Cancer 66, 191-196.
4. Bardi G, Fenger C, Johansson B, Mitelman F, and Heim S (2004). Tumor karyotype predicts clinical outcome in colorectal cancer patients. J Clin Oncol 22, 2623-2634.
5. Duesberg P, Li R, and Rasnick D (2004). Aneuploidy approaching a perfect score in predicting and preventing cancer: highlights from a conference held in Oakland, CA in January, 2004. Cell Cycle 3, 823-828.
6. Lengauer C, Kinzler KW, and Vogelstein B (1997). Genetic instability in colorectal cancers. Nature 386, 623-627.
7. Lengauer C, Kinzler KW, and Vogelstein B (1998). Genetic instabilities in human cancers. Nature 396, 643-649.
8. Shoemaker RH, Monks A, Alley MC, Scudiero DA, Fine DL, McLemore TL, Abbott BJ, Paull KD, Mayo JG, and Boyd MR (1988). Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res 276, 265-286.
9. Weinstein JN and Pommier Y (2006). Connecting genes, drugs and diseases. Nat Biotechnol 24, 1365-1366.
10. Weinstein JN (2006). Spotlight on molecular profiling: "integromic" analysis of the NCI-60 cancer cell lines. Mol Cancer Ther 5, 2601-2605.
11. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, and Kirsch IR (2003). Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63, 8634-8647.
12. Roschke AV, Lababidi S, Tonon G, Gehlhaus KS, Bussey K, Weinstein JN, and Kirsch IR (2005). Karyotypic "state" as a potential determinant for anticancer drug discovery. Proc Natl Acad Sci USA 102, 2964-2969.
13. Wallqvist A, Huang R, Covell DG, Roschke AV, Gelhaus KS, and Kirsch IR (2005). Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells. Mol Cancer Ther 4, 1559-1568.
14. Roschke AV and Kirsch IR (2005). Targeting cancer cells by exploiting karyotypic complexity and chromosomal instability. Cell Cycle 4, 679-682.
15. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, et al. (2007). Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 6, 820-832.
16. Ihaka R and Gentleman R (1996). R: a language for data analysis and graphics. J Comput Graph Stat 5, 299-314.
17. Gentleman R, Carey V, Huber W, Irizarry R, and Dudoit S (2005). Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York, NY: Springer.
18. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, and Speed TP (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264.
19. Simon R and Lam A (2007). BRB-ArrayTools. Version 3.6. http://linus.nci.nih.gov/brb.
20. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, and Lempicki RA (2003). DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4, P4.
21. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, and Lempicki RA (2003). Identifying biological themes within lists of genes with EASE. Genome Biol 4, R70.
22. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, and Vogelstein B (1998). Mutations of mitotic checkpoint genes in human cancers. Nature 392, 300-303.
23. Imai Y, Shiratori Y, Kato N, Inoue T, and Omata M (1999). Mutational inactivation of mitotic checkpoint genes, hsMAD2 and hBUB1, is rare in sporadic digestive tract cancers. Jpn J Cancer Res 90, 837-840.
24. Sato M, Sekido Y, Horio Y, Takahashi M, Saito H, Minna JD, Shimokata K, and Hasegawa Y (2000). Infrequent mutation of the hBUB1 and hBUBR1 genes in human lung cancer. Jpn J Cancer Res 91, 504-509.
25. Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K, and Hirata Y (2002). Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res 62, 13-17.
26. Ru HY, Chen RL, Lu WC, and Chen JH (2002). hBUB1 defects in leukemia and lymphoma cells. Oncogene 21, 4673-4679.
27. Wang X, Jin DY, Ng RW, Feng H, Wong YC, Cheung AL, and Tsao SW (2002). Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res 62, 1662-1668.
28. Wang X, Jin DY, Wong YC, Cheung AL, Chun AC, Lo AK, Liu Y, and Tsao SW (2000). Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis 21, 2293-2297.
29. Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W, Dobles M, Sorger PK, Murty VV, and Benezra R (2001). MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 409, 355-359.
30. Michel L, Benezra R, and Diaz-Rodriguez E (2004). MAD2 dependent mitotic checkpoint defects in tumorigenesis and tumor cell death: a double edged sword. Cell Cycle 3, 990-992.
31. Dai W, Wang Q, Liu T, Swamy M, Fang Y, Xie S, Mahmood R, Yang YM, Xu M, and Rao CV (2004). Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res 64, 440-445.
32. Kalitsis P, Fowler KJ, Griffiths B, Earle E, Chow CW, Jamsen K, and Choo KH (2005). Increased chromosome instability but not cancer predisposition in haploinsufficient Bub3 mice. Genes Chromosomes Cancer 44, 29-36.
33. Schmidt M and Medema RH (2006). Exploiting the compromised spindle assembly checkpoint function of tumor cells: dawn on the horizon? Cell Cycle 5, 159-163.
34. Chen JJ, Peck K, Hong TM, Yang SC, Sher YP, Shih JY, Wu R, Cheng JL, Roffler SR, Wu CW, et al. (2001). Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 61, 5223-5230.
35. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
36. Kluger HM, Kluger Y, Gilmore-Hebert M, DiVito K, Chang JT, Rodov S, Mironenko O, Kacinski BM, Perkins AS, and Sapi E (2004). cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab Invest 84, 320-331.
37. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, and Chinnaiyan AM (2004). Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101, 9309-9314.
38. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, Naber SP, and Weinberg RA (2005). The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet 37, 1047-1054.
39. Gupta GP and Massague J (2006). Cancer metastasis: building a framework. Cell 127, 679-695.
40. Huber MA, Kraut N, and Beug H (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17, 548-558.
41. Kopfstein L and Christofori G (2006). Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 63, 449-468.